系列氯胺酮输注作为抑郁症住院治疗辅助疗法的随机临床试验
KARMA-Dep 2 是一项在爱尔兰开展的双盲、随机、咪达唑仑对照实用性试验,纳入65例住院重性抑郁发作成人(基线MADRS≥20)。结果显示,8次氯胺酮输注(0.5 mg/kg)在改善抑郁症状方面不优于咪达唑仑(0.045 mg/kg),主要结局MADRS差值无统计学意义,次要结局亦无显著差异。
要点
- 系列辅助氯胺酮输注在住院抑郁患者中未优于活性对照咪达唑仑。
- 多数患者和评估者能准确猜测治疗分配,盲法可能受影响。
核心结论
- 系列辅助氯胺酮输注在减少住院抑郁患者抑郁症状方面不优于系列咪达唑仑输注。
研究设计与样本
- 研究者发起的双盲、随机、咪达唑仑对照实用性试验,在爱尔兰一个学术中心于2021年9月至2024年8月开展。
- 纳入65例≥18岁、DSM-5重性抑郁发作(单相或双相)且基线MADRS≥20的住院成人,随机1:1分配,62例纳入最终分析。
- 干预为最多8次每周两次静脉输注氯胺酮(0.5 mg/kg)或咪达唑仑(0.045 mg/kg),作为常规住院精神科治疗的辅助,随访6个月。
主要发现
- 认知、成本效果和生活质量等其他次要结局均无显著组间差异。
- 多数患者和评估者准确猜测了治疗分配。
关键数值与推荐
- 主要结局为观察者评定的MADRS从基线至治疗结束的变化。
- 氯胺酮剂量0.5 mg/kg,咪达唑仑剂量0.045 mg/kg,最多8次每周两次静脉输注。
临床怎么用
- 对于住院接受常规精神科治疗的重性抑郁发作患者,系列辅助氯胺酮输注未显示优于活性对照的短期疗效。
- 临床决策时应结合盲法可能受损及本研究样本量有限的局限,审慎解读氯胺酮的超说明书使用。
局限性
- 样本量较小,随机65例、最终分析62例。
- 多数患者和评估者能准确猜测治疗分配,盲法可能受损。
- 单中心实用性试验,外推性受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Serial ketamine infusions are being increasingly adopted as off-label treatment for major depression in routine clinical practice, yet robust psychoactive placebo-controlled trial evidence for short- and long-term efficacy and safety remains limited. OBJECTIVE: To assess antidepressant efficacy, safety, tolerability, cost-effectiveness, and quality of life during and after serial ketamine infusions compared with midazolam as an adjunct to usual inpatient care. DESIGN, SETTING, AND PARTICIPANTS: The KARMA-Dep 2 trial was an investigator-led, double-blind, randomized, midazolam-controlled, pragmatic trial conducted at an academic center in Ireland between September 2021 and August 2024. Participants included adults (≥18 years) hospitalized with a DSM-5 major depressive episode (unipolar or bipolar) and baseline Montgomery-Åsberg Depression Rating Scale (MADRS) score ≥20. INTERVENTIONS: Participants were randomized 1:1 to receive up to 8 twice-weekly intravenous infusions of either ketamine (0.5 mg/kg) or midazolam (0.045 mg/kg) as an adjunct to usual-care pharmacotherapy and other aspects of routine inpatient psychiatric care. Participants were followed up for 6 months. MAIN OUTCOMES AND MEASURES: The primary outcome was change in depression symptom severity measured by the observer-rated MADRS score from baseline to end of treatment. Secondary outcomes included self-reported depression severity, safety, tolerability, health care costs, and quality of life. RESULTS: Of 65 randomized participants (mean [SD] age, 53.5 [18.6] years; 37 [59.7%] male), 62 were included in the final analysis. In the analysis of primary outcome, end-of-treatment MADRS scores did not significantly differ between the ketamine and midazolam groups (adjusted mean difference, -3.16 points, 95% CI, -8.54 to 2.22; P = .25; Cohen d, -0.29). Similarly, there was no significant between-group difference between Quick Inventory of Depressive Symptoms, Self-Report, scores (adjusted mean difference, -0.002; 95% CI, -2.71 to 2.71; P > .99; Cohen d, -0.0004). There were no significant between-group differences on other secondary outcomes, including cognition, cost-effectiveness, or quality of life. Most patients and raters accurately guessed treatment allocation. CONCLUSIONS AND RELEVANCE: Serial adjunctive ketamine infusions were not more effective than serial midazolam infusions in reducing depressive symptoms in inpatients receiving usual psychiatric care. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04939649.
引用
- Jelovac A, McCaffrey C, Terao M, et al. Serial Ketamine Infusions as Adjunctive Therapy to Inpatient Care for Depression: The KARMA-Dep 2 Randomized Clinical Trial. JAMA Psychiatry. 2025. PMID: 41123905. doi:10.1001/jamapsychiatry.2025.3019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。